BR112015000616A2 - tratamento da esclerose múltipla com combinação de laquinimode e fampridina - Google Patents

tratamento da esclerose múltipla com combinação de laquinimode e fampridina

Info

Publication number
BR112015000616A2
BR112015000616A2 BR112015000616A BR112015000616A BR112015000616A2 BR 112015000616 A2 BR112015000616 A2 BR 112015000616A2 BR 112015000616 A BR112015000616 A BR 112015000616A BR 112015000616 A BR112015000616 A BR 112015000616A BR 112015000616 A2 BR112015000616 A2 BR 112015000616A2
Authority
BR
Brazil
Prior art keywords
laquinimode
fampridine
multiple sclerosis
combination
provides
Prior art date
Application number
BR112015000616A
Other languages
English (en)
Inventor
Kaye Joel
Tarcic Nora
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112015000616A2 publication Critical patent/BR112015000616A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

resumo tratamento da esclerose múltipla com combinação de laquinimode e fampridina essa invenção fornece um método de tratamento de um indivíduo afligido com esclerose múltipla ou apresentando uma síndrome clinicamente isolada, compreendendo administrar fampridina ao indivíduo como uma terapia complementar ou juntamente com laquinimode. essa invenção também fornece um pacote que compreende laquinimode e fampridina para tratar um indivíduo afligido com esclerose múltipla ou apresentando uma síndrome clinicamente isolada. essa invenção também fornece fampridina para uso como uma terapia complementar ou juntamente com laquinimode, no tratamento de um indivíduo afligido com esclerose múltipla ou apresentando uma síndrome clinicamente isolada. essa invenção também fornece uma composição farmacêutica que compreende laquinimode e fampridina para uso no tratamento de um indivíduo afligido com esclerose múltipla ou apresentando uma síndrome clinicamente isolada. essa invenção fornece, adicionalmente, o uso de laquinimode e fampridina na preparação de uma combinação para tratar um indivíduo afligido com esclerose múltipla ou apresentando uma síndrome clinicamente isolada.
BR112015000616A 2012-07-12 2013-07-11 tratamento da esclerose múltipla com combinação de laquinimode e fampridina BR112015000616A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12
PCT/US2013/050001 WO2014011827A1 (en) 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine

Publications (1)

Publication Number Publication Date
BR112015000616A2 true BR112015000616A2 (pt) 2017-06-27

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000616A BR112015000616A2 (pt) 2012-07-12 2013-07-11 tratamento da esclerose múltipla com combinação de laquinimode e fampridina

Country Status (16)

Country Link
US (2) US20140017226A1 (pt)
EP (1) EP2872217A4 (pt)
JP (1) JP2015522077A (pt)
KR (1) KR20150038072A (pt)
CN (1) CN104582793A (pt)
AR (1) AR091724A1 (pt)
AU (1) AU2013290181A1 (pt)
BR (1) BR112015000616A2 (pt)
CA (1) CA2873229A1 (pt)
EA (1) EA201590191A1 (pt)
HK (1) HK1209672A1 (pt)
IL (1) IL236230A0 (pt)
MX (1) MX2015000485A (pt)
TW (1) TW201408300A (pt)
UY (1) UY34896A (pt)
WO (1) WO2014011827A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
SG11201608674UA (en) * 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
AR073573A1 (es) * 2008-09-10 2010-11-17 Acorda Therapeutics Inc Metodos para utilizar composiciones de aminopiridina de liberacion sostenida
PL2442651T3 (pl) * 2009-06-19 2015-12-31 Teva Pharma Leczenie stwardnienia rozsianego za pomocą lakwinimodu
CN103974704A (zh) * 2011-10-12 2014-08-06 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

Also Published As

Publication number Publication date
WO2014011827A1 (en) 2014-01-16
UY34896A (es) 2014-02-28
KR20150038072A (ko) 2015-04-08
US20160235735A1 (en) 2016-08-18
AU2013290181A1 (en) 2015-02-26
TW201408300A (zh) 2014-03-01
IL236230A0 (en) 2015-01-29
HK1209672A1 (en) 2016-04-08
US20140017226A1 (en) 2014-01-16
JP2015522077A (ja) 2015-08-03
EP2872217A4 (en) 2016-03-16
EP2872217A1 (en) 2015-05-20
CN104582793A (zh) 2015-04-29
CA2873229A1 (en) 2014-01-16
MX2015000485A (es) 2015-04-08
EA201590191A1 (ru) 2015-06-30
AR091724A1 (es) 2015-02-25

Similar Documents

Publication Publication Date Title
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112015011933A8 (pt) Composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112015006623A2 (pt) laquinimod e pridopidina para o tratamento de doenças neurodegenerativas
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112014027047A2 (pt) nova formulação
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
BR112016013754A2 (pt) Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.